Wockhardt Limited submitted a press release regarding the award of high susceptibility breakpoints to Zaynich by the Clinical and Laboratory Standards Institute. The press release highlights that this is the first time an antibiotic has received such a high breakpoint for multiple Gram-negative pathogen families.
Wockhardt Limited has informed the Exchange regarding a press release dated Jun 28, 2024, titled "Globally renowned US body Clinical and Laboratory Standards Institute (CLSI) awards high susceptibility breakpoints to Zaynich (Zidebactam/Cefepime- WCK 5222)".